iCAN science seminar on Deciphering the Genomics of Aggressive Lymphomas with Dr. Daniel Hodson

Warm welcome to the iCAN science seminar and to the public examination of Leo Meriranta with Dr. Hodson as the opponent on Fri, September 20!

Speaker: Dr. Daniel Hodson, MD, PhD

Talk title: Deciphering the Genomics of Aggressive Lymphomas

When: Fri 20.9. at 9:00-10:00
Where: Biomedicum 1, Skutsi, and online

Zoom-link (Meeting ID: 648 0498 6682 Passcode: 366409)

Host: Prof. Sirpa Leppä


Minibio

Dr Hodson studied medicine at Cambridge and Oxford Universities before training in clinical haematology in Cambridge. He undertook a University of Cambridge PhD in molecular immunology supervised by Dr Martin Turner at the Babraham Institute. In 2010 he moved as a Kay Kendall Leukaemia Fund (KKLF) Post-doctoral Fellow to the lab of Dr Louis Staudt at the National Cancer Institute, NIH, USA to study the functional genomics of aggressive B cell lymphoma. In 2015 he was awarded a Medical Research Council (MRC) Clinician Scientist Fellowship and returned to Cambridge to establish a research group in the Welcome MRC Cambridge Stem Cell Institute, University of Cambridge. In 2021 he was awarded a Cancer Research UK Senior Research Fellowship and in 2023 a European Research Council Consolidator award.

The Hodson Group researches the molecular mechanisms that underlie lymphomagenesis with a view to identifying new targets for designer anti-lymphoma therapies. Key themes in his lab are molecular profiling (especially ctDNA) to resolve genetic heterogeneity of DLBCL, novel approaches to model the functional genetics of lymphoma, and the mechanistic contribution of RNA helicases in lymphomagenesis. Dr Hodson is also a practising clinician and an honorary Haematology consultant. He runs an active portfolio of clinical trials to study the effect of novel therapies in patients with lymphoma and chairs the UK NCRI Lymphoma Translational Science Subgroup.


Key Publications

Gong C, Krupka JA, Gao J, Grigoropoulos NF, Giotopoulos G, Asby R, Screen M, Usheva Z, Cucco F, Barrans S, Painter D, Zaini NBM, Haupl B, Bornelöv S, Ruiz De Los Mozos I, Meng W, Zhou P, Blain AE, Forde S, Matthews J, Khim Tan MG, Burke GAA, Sze SK, Beer P, Burton C, Campbell P, Rand V, Turner SD, Ule J, Roman E, Tooze R, Oellerich T, Huntly BJ, Turner M, Du MQ, Samarajiwa SA, Hodson DJ. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Mol Cell. 2021 Oct 7;81(19):4059-4075. PMID: 34437837 

Morin RD, Arthur SE, Hodson DJ. Molecular profiling in diffuse large B-cell lymphoma: why so many types of subtypes? Br J Haematol. 2021 Aug 31. PMID: 34467527

Gao J, Sidiropoulou E, Walker I, Krupka JA, Mizielinski K, Usheva Z, Samarajiwa SA, Hodson DJ. SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence. Blood. 2021 Sep 16;138(11):959-964. PMID: 33988691

Caeser R, Di Re M, Krupka JA, Gao J, Lara-Chica M, Dias J, Cooke S, Fenner R, Usheva Z, Runge H, Beer PA, Eldaly H, Pak HK, Park CS, Vassiliou G, Huntly BJP, Mupo A, Bashford-Rogers RJM & Hodson DJ.    Genetic modification of primary human B cells generates translationally-relevant models of high-grade lymphoma. Nature Communications. 2019 Oct 4;10(1):4543. PMID: 31586074

Caeser R, Gao, J, Di Re M, Gong J & Hodson DJ.  Genetic manipulation and immortalized culture of ex vivo primary human germinal center B cells.  Nature Protocols. 2021 Apr 9. doi: 10.1038/s41596-021-00506-4. Online ahead of print. PMID: 33837304
 

Lacey S, Barrans S, Beer P, Painter D, Smith A, Roman E, Cooke S, Ruiz C, Glover P, Van Hoppe S, Webster N, Campbell P, Tooze R, Patmore R, Burton C, Crouch S & Hodson DJ. Targeted sequencing in DLBCL, molecular subtypes and outcomes: a Haematological Malignancy Research Network report. Blood. 2020 May 14;135(20):1759-1771. PMID: 32187361 

For more information on the seminar series, please contact ican-comms@helsinki